About DMC Biotechnologies
DMC Biotechnologies is a private company based in Boulder, Colorado. It has reported $48,147,284 raised in eight offerings on Form D since January 2018. Its chief executive is Jim Flatt.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | Dec 30, 2025 | $1,414,267of $2.5M target | 7 | $202K | Equity, Debt, Options, Securities on exercise, Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversionRule 506(b) | Form D ↗ |
| Oct 31, 2025 | Dec 30, 2025 | $904,500of $1.6M target | 4 | $226K | Equity, Debt, Options, Securities on exercise, Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversionRule 506(b) | Form D ↗ |
| Apr 8, 2025 | Apr 23, 2025 | $4,791,203of $10.0M target | 9 | $532K | Equity, Debt, Options, Securities on exercise, Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversionRule 506(b) | Form D ↗ |
| Aug 11, 2022 | Aug 24, 2022 | $66,720fully sold | 1 | $66,720 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 30, 2021 | Dec 10, 2021 | $33,760,493of $43.5M target | 12 | $2.8M | EquityRule 506(b) | Form D ↗ |
| Jan 14, 2021 | Jan 28, 2021 | $22,446fully sold | 1 | $22,446 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 18, 2019 | Jun 27, 2019 | $4,649,995of $12.0M target | 3 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Jan 4, 2018 | Jan 18, 2018amended Mar 15, 2019 | $2,537,660fully sold | 3 | $845K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Total, eight offerings | $48,147,284 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on DMC Biotechnologies's Form D filed Dec 30, 2025.
JY
Josh Yelen
Executive officer
JB
Josko Bobanovic
Director
RM
Rob van der Meij
Director
KJ
K'Lynne Johnson
Director
AC
Alastair Cooper
Director
JF
Jim Flatt
Chief Executive Officer and director
DC
Doug Cameron
Director
ML
Matthew Lipscomb
Director
Earlier filings also listed Michael Lynch (director, last listed Aug 2022), Carolyn Fritz (director, last listed Aug 2022) and Ashley Jenkins (executive officer, last listed Aug 2022).